STING drives CD4+ T cell differentiation via JAK-STAT signaling in Bullous Pemphigoid immunopathogenesis

Bullous Pemphigoid (BP) is a debilitating autoimmune blistering disease with rising incidence, yet its precise immune regulatory mechanisms remain largely undefined. Current treatments often involve broad immunosuppression, leading to significant side effects. The stimulator of interferon genes (STING) pathway is a crucial link between innate and adaptive immunity, increasingly implicated in various autoimmune conditions. Understanding STING's role in modulating CD4+ T cell responses could unveil novel, targeted therapeutic strategies for BP.

Researchers investigated STING's role in Bullous Pemphigoid by comparing lesional skin tissues from BP patients with healthy controls. They performed transcriptomic analysis on peripheral blood CD4+ T cells from BP patients to identify differentially expressed genes and enriched pathways. To confirm causality, they used the pharmacological STING inhibitor C176 to assess its impact on aberrant signaling pathways. qRT-PCR analysis was employed to quantify mRNA levels of specific molecules like STING1, JAK1, and CXCR5 in patient samples and after C176 treatment.

STING expression was found to be significantly increased in lesional skin tissues from Bullous Pemphigoid patients compared to healthy controls. Transcriptomic analysis of peripheral blood CD4+ T cells from BP patients revealed significant enrichment in pathways related to JAK-STAT signaling, T cell activation and differentiation, and type I interferon (IFN-I) responses. Pharmacological inhibition with C176 markedly attenuated the aberrant activation of these identified signaling pathways. > qRT-PCR analysis further confirmed that mRNA levels of STING1, JAK1, and CXCR5 were significantly elevated in BP patients, and C176 treatment suppressed the expression of these molecules. These findings collectively suggest a direct role for STING in driving BP immunopathogenesis.